Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

Journal of Clinical Investigation

Volumn 115, Issue 11, 2005, Pages 2992-3006

  Vincent, Loïc ^a   Kermani, Pouneh ^a   Young, Lauren M ^a   Cheng, Joseph ^a   Zhang, Fan ^a   Shido, Koji ^a   Lam, George ^a   Bompais Vincent, Heidi ^b   Zhu, Zhenping ^c   Hicklin, Daniel J ^c   Bohlen, Peter ^c   Chaplin, David J ^d   May, Chad ^c   Rafii, Shahin ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d OXiGENE Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; COMBRETASTATIN A4 PHOSPHATE; MONOCLONAL ANTIBODY; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULAR ENDOTHELIAL CADHERIN ANTIBODY; VIRUS PROTEIN;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TUMOR REGRESSION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA CATENIN; CADHERINS; CAPILLARIES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STILBENES;

EID: 27644466314     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24586     Document Type: Article

References (35)

1. Zhu, Z., et al. 2003. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 17:604-611.
2. Dejana, E. 1996. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J. Clin. Invest. 98:1949-1953.
3. Breviario, F., et al. 1995. Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. Arterioscler. Thromb. Vasc. Biol. 15:1229-1239.
4. Carmeliet, P., et al. 1999. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 98:147-157.
5. Caveda, L., et al. 1996. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J. Clin. Invest. 98:886-893.
6. Corada, M., et al. 1999. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:9815-9820.
7. Bach, T.L., et al. 1998. VE-cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp. Cell Res. 238:324-334.
8. Liao, F., et al. 2000. Monoclonal antibody to VE-cadherin is a potent inhibitor to angiogenesis, tumor growth, and metastasis. Cancer Res. 60:6805-6812.
9. Liao, F., et al. 2002. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 62:2567-2575.
10. Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:389-395.
11. Yancopoulos, G.D., et al. 2000. Vascular-specific growth factors and blood vessel formation. Nature. 407:242-248.
12. Jain, R. K., and Carmeliet, P. 2001. Vessels of death or life. Sci. Am. 285:38-45.
13. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1:27-31.
14. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364.
15. Risau, W. 1997. Mechanisms of angiogenesis. Nature. 386:671-674.
16. Denekamp, J. 1993. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66:181-196.
17. Chaplin, D.J., Pettit, G.R., Parkins, C.S., and Hill, S.A. 1996. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer. 27:S86-S88.
18. Chaplin, D.J., Pettit, G.R., and Hill, S.A. 1999. Antivascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 19:189-195.
19. Chabner, B.A., and Horwitz, S.B. 1990. Plant alkaloids. Cancer Chemother. Eid. Response Modif. 11:74-81.
20. McGown, A.T., and Fox, B.W. 1989. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des. 3:249-254.
21. Pettit, G.R., et al. 1989. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45:209-211.
22. Dark, G.G., et al. 1997. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1829-1834.
23. Iyer, S., et al. 1998. Induction ofapoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58:4510-4514.
24. Grosios, K., Holwell, S.E., McGown, A.T., Pettit, G.R., and Bibby, M.C. 1999. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer. 81:1318-1327.
25. Galbraith, S.M., et al. 2001. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21:93-102.
26. Esser, S., Lampugnani, M.G., Corada, M., Dejana, E., and Risau, W. 1998. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111:1853-1865.
27. Zhang, F., et al. 2004. Adenovirus E4 gene promotes selective endothelial cell survival and angiogenesis via activation of the vascular endothelial-cadherin/Akt signaling pathway. J. Biol. Chem. 279:11760-11766.
28. Orford, K., Crockett, C., Jensen, J.P., Weissman, A.M., and Byers, S.W. 1997. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem. 272:24735-24738.
29. Liu, C., et al. 1999. beta-Trcp couples beta-catenin phosphorylation- degradation and regulates Xenopus axis formation. Proc. Natl. Acad. Sci. U. S. A. 96:6273-6278.
30. May, C., et al. 2005. Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Bleed. 105:4337-4344.
31. + endothelial cells and systemic mobilization of hematopoietic progenitors. J. Clin. Invest. 115:653-663. doi:10.1172/JCI200522655.
32. Grossmann, J. 2002. Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis. 7:247-260.
33. Weis, S., et al. 2004. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113:885-894. doi:10.1172/JCI200420702.
34. Jain, R.K. 2003. Molecular regulation of vessel maturation. Nat. Med. 9:685-693.
35. Winkler, F., et al. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6:553-563.